CD40LG and breast carcinoma: To investigate the clinical relevance of the in vivo performance of sLip with inter-individual properties of anti-PEG IgM and complement capacity, a clinical trial of 7 patients with breast cancer (female, aged 34–65) treated by PEGylated liposomal doxorubicin (Duomeisu®) was conducted.